Publish date: 16 February 2023
Przeczytasz w 3 min
The AIOO® software and GPS™ test developed by the INVICTA Research and Development Center have been qualified to participate in the Start-Up-Med 2023 contest, which is an accompanying event of the 8th edition of the Health Challenges Congress. The voting is open until February 23rd.
The aim of the competition is to select and recognize innovative solutions in medicine that can have a significant impact on patients and the healthcare system. The competition includes projects involving broadly defined medical technologies, both pharmaceutical and non-pharmaceutical technologies (including medical devices, diagnostic solutions, and teleinformatics technologies).
The finalists will be invited to present their innovations during the Health Challenges Congress, where the jury will ultimately determine the winners of the Start-Up-Med 2023 competition.
We know that our innovations deserve this recognition 😊 That’s why we are mobilizing our forces and encouraging everyone to vote!
You can cast your vote for AIOO® and GPS™ here:
AIOO®
Artificial Intelligence Oocytes is a unique, proprietary software developed by the research and development team at INVICTA Research Center. It provides personalized predictions of the probable number of mature oocytes that can be obtained in the in vitro fertilization process. Based on artificial intelligence, the software forecasts the likely outcome of ovarian stimulation in a patient, depending on the stimulation protocol and the doses of gonadotropins used.
AIOO® is exclusively available at INVICTA Clinics.
GPS™
Genetic Prediction of Stimulation is a test that further enhances the accuracy of the predictions generated by AIOO® regarding the number of mature oocytes attainable during in vitro stimulation. The increased accuracy is achieved by GPS™, which is developed using artificial intelligence algorithms to identify the genetic markers that influence a patient’s predisposition to hormonal stimulation response.
